Editorial Policy

Biotech Cancer Conference Coverage (also known as Biotech Strategy Blog) provides commentary and insight on oncology & hematology new product development in the pharma and biotech industries.

Our cancer conference coverage focuses primarily on clinical data presented at medical and scientific meetings run by societies and organizations such as AACR, ASCO, ASH, EHA, AUA, EAU, SITC & ESMO/ECCO.

Occasionally covered are themes such as innovation, nanotechnology, regenerative medicine, strategic issues in the biotechnology industry and promising scientific research in other therapeutic areas such as osteoporosis, respiratory medicine and Alzheimer’s disease.

All the content is editorially independent, no post is sponsored and no paid advertising is accepted. Posts reflect the opinion of the author and not those of any employer or company. Unsolicited guest posts are not accepted. 

Some content (“Premium Content”) requires payment of a fee to access. All posts from 2010 and 2011 are free and open access.

By accessing or using this website, you accept and agree to the Terms of Use. These should be really carefully as upon acceptance they form a contract that governs your use of this site and purchase of Premium Content. If you do not wish to accept the Terms of Use you should not access or use this website.

Editor & Oncology Lead Writer

Sally Church with @Gene_Antibody at ASCO 2014

Picture Credit: @Gene_Antibody at ASCO 2014

From September 2013, Sally Church, PhD has become the Editor of Biotech Cancer Conference Coverage and lead writer for oncology related content.

Recognized as an industry expert (she has appeared on CNBC and been widely quoted in the media, including NPR), Sally is considered to be one of the Top 50 women on Twitter, where as @MaverickNY she is a frequent commentator on oncology drug development. Sally uses the author name “MaverickNY” to identify her posts on this blog.

Since 2006 Sally has written the widely acclaimed Pharma Strategy Blog which showcases her knowledge of cancer biology and new product development. As part of her “Making a Difference” series she regularly conducts interviews with oncology thought leaders.

Gleevec on cover of Time MagazineWith over 20 years experience in the pharmaceutical industry in the UK & United States, Sally has held executive positions in sales, marketing and new product development, and has received numerous business achievement awards.

At Novartis Oncology she co-led the initial US launches of Gleevec® in CML and GIST. Through her company, Icarus Consultants, Sally helps pharma & biotech companies understand the oncology market, and focus on the right target and commercial opportunity for new products.

Sally’s qualifications includes a PhD from Kings College London, MBA from Rutgers, Master of Science in Human & Applied Physiology and undergraduate degree in Sports Science. She is a keen sportswomen who has played at national and county level in cricket and hockey in the UK. Sally has also undertaken executive education in finance at Harvard Business School.

She devotes some of her spare time to charitable cancer causes and sits on the board of directors of a non-profit organization, GRACE (Global Resource for Advancing Cancer Education) which focuses primarily on lung cancer education.

Sally is a member of the National Association of Science Writers (NASW).

Contributing Writer

Pieter Droppert (@3NT) writes about drug development, innovation and clinical data that captures his attention at medical meetings.

Guest Writers

Posts may be authored by invited guest writers. Author attribution is given in each post.